Clinical Trial Update: A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating capecitabine (Xeloda) as adjuvant therapy after surgical resection of colon cancer. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Capecitabine (Xeloda) (Capecitabine)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Colorectal Cancer | Phase 4 | Status: COMPLETED